Our top pick for
Cue Biopharma Inc is a biotechnology business based in the US. Cue Biopharma shares (CUE) are listed on the NASDAQ and all prices are listed in US Dollars. Cue Biopharma employs 50 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$12.23|
|52-week range||$9.65 - $16.75|
|50-day moving average||$13.04|
|200-day moving average||$12.34|
|Wall St. target price||$29.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.44|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-2.94%|
|1 month (2021-09-23)||-17.97%|
|3 months (2021-07-23)||16.59%|
|6 months (2021-04-23)||0.25%|
|1 year (2020-10-22)||-10.07%|
|2 years (2019-10-22)||60.71%|
|3 years (2018-10-22)||80.92%|
|5 years (2016-10-19)||N/A|
|Revenue TTM||$5.5 million|
|Gross profit TTM||$-30,391,380|
|Return on assets TTM||-28.74%|
|Return on equity TTM||-57.39%|
|Market capitalisation||$397 million|
TTM: trailing 12 months
There are currently 2.0 million Cue Biopharma shares held short by investors – that's known as Cue Biopharma's "short interest". This figure is 15.4% down from 2.4 million last month.
There are a few different ways that this level of interest in shorting Cue Biopharma shares can be evaluated.
Cue Biopharma's "short interest ratio" (SIR) is the quantity of Cue Biopharma shares currently shorted divided by the average quantity of Cue Biopharma shares traded daily (recently around 293761.16788321). Cue Biopharma's SIR currently stands at 6.85. In other words for every 100,000 Cue Biopharma shares traded daily on the market, roughly 6850 shares are currently held short.
However Cue Biopharma's short interest can also be evaluated against the total number of Cue Biopharma shares, or, against the total number of tradable Cue Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cue Biopharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Cue Biopharma shares in existence, roughly 60 shares are currently held short) or 0.079% of the tradable shares (for every 100,000 tradable Cue Biopharma shares, roughly 79 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cue Biopharma.
Find out more about how you can short Cue Biopharma stock.
We're not expecting Cue Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Cue Biopharma's shares have ranged in value from as little as $9.652 up to $16.745. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cue Biopharma's is 1.6181. This would suggest that Cue Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 would also leverage the IL-2 based CUE-100 framework and target an antigen to be selected in collaboration with LG Chem; CUE-200 framework that utilizes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences to the development of Immuno-STATs focused in the field of oncology; and Albert Einstein College of Medicine.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.